Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health: Psychology

New Dental office, Dentist At Plum Creek, coming to Plum Creek neighborhood of Kyle.

Leave a comment


Dentist in Kyle TX “We are so thrilled to have support from our Kyle community that we are excited to open second location in Plum Creek neighborhood so we can serve more patients. With a neighborhood dental clinic, it will increase convenience for patients and avoid driving in crazy Austin traffic” says Dr. Dholariya.

KYLE, Texas, Aug. 23, 2023 /PRNewswire-PRWeb/ — Dentist At Plum Creek will be a modern dental practice that provides comprehensive dental care to patients of all ages. Dr. Mahesh Dholariya and his team of dental specialists is providing quality care ranging from simple to complex cases at their first location, Kyle Parkway Dentistry, since 2016. Adding an another location, will help to serve more patients so they don’t have to wait for longer period to get an appointments at our main location. It will also help to bring in more specialty services such as dental implants and Invisalign to Kyle community members.

Dr. Dholariya earned his DDS degree from The University of Texas Health Science Center Dental School at San Antonio. Dr. D is committed to pursuing ongoing professional development through continuing education.

About Dentist At Plum Creek:

Dentist At Plum Creek offers an expansive menu of dental services, including general and restorative dentistry as well as Invisalign and cosmetic dental procedures. The practice mission is to provide state-of the-art dentistry while adhering to each patient’s need for comfort and convenience. They offer several relaxing office amenities and provide flexible scheduling such as family block appointments and extended hours.

For more information from Dentist At Plum Creek, visit the practice website at DentistAtPlumCreek.com or call 512-256-0206.

SOURCE Dentist At Plum-Creek

Health: Mental Health

TurnCare partners with Monetize360 to effectively scale its Patient Management Solution, driving revenue and increasing customer satisfaction

Leave a comment


Monetize360’s ability to ingest, rationalize, and analyze millions of IoT data points sets new standard for flexibility, accuracy, and depth

LOS ALTOS, Calif., Aug. 23, 2023 /PRNewswire-PRWeb/ — TurnCare has selected Monetize360, a leading Agile Monetization company, to drive, support, and enable utilization-driven billing data capture for their first-of-its-kind Intelligent Support Surface Patient Management Solution. The company chose Monetize360 because of its singular ability to handle the challenges of complex, usage-based billing models at scale without requiring intensive engineering resources.

TurnCare is a Patient Management company that helps hospital patients a) avoid adverse events like Hospital Acquired Pressure Injuries, b) mobilize more quickly, and c) experience greater comfort, all without putting more work effort on Nursing staff and leaders. The company’s Guardian System uses patented VasoTactic technology to prevent the compression of blood vessels in the sacral region, avoiding the degradation of blood flow in low mobility / high acuity patients. Hospitals only pay for TurnCare when they use it for specific patients. This relationship-level, patient-specific, usage-based billing is vital for today’s hospitals that want control over spending.

Historically this level of granularity has been incredibly complicated to deliver, as each health system usually has different usage models and associated rates. As a result, traditionally Health-Tech solution providers are forced to create their own systems from scratch with a dedicated development team, compromise on timeliness or accuracy, or be less flexible in shaping billing to customers’ wants. Monetize 360 enables TurnCare to realize the benefits without custom-developing a software application.

With more than a dozen hospitals and health systems and over 50,000 patients managed, Monetize360’s powerful backend platform ingests usage events and rates them based on nearly limitless criteria, enabling TurnCare to identify the precise usage per day, per device, per agreed-upon cost structures. With an intuitive front end, almost anyone within TurnCare can analyze revenue in moments instead of days to weeks.

“We evaluated several market options, but as soon as we saw Monetize360’s platform, we were blown away. Monetize360 gave us the accuracy and customization we wanted – and needed – to offer our healthcare system customers. With Monetize360, we can make necessary changes quickly, which gives us flexibility as we deploy new products and services and evolve our billing models as we grow. Since deploying Monetize360, we’ve seen a significant uptick in revenue and increased customer satisfaction. Monetize 360’s support has been first-rate: delivering excellent quality and fast turnaround. The entire experience has been a win-win for us and our customers,” said Kim Orumchian, CEO, cofounder, TurnCare.

“The Monetization Cloud offers a 360-degree view of customer contract, usage, and billing data, a high degree of accuracy, and nearly limitless dimensions, allowing for fast configuration without significant effort,” said Jayaram Bhat, CEO of Monetize360. He added, “TurnCare is a best-in-class Healthtech company. They set a high bar from the integrity they bring to customers and patient relationships to the precision of their business operations and innovation of their product and vision. We are thrilled to be their partner of choice as they elevate their monetization models.”

About Monetize360
Monetize360 is on a mission to eliminate the cost and complexities associated with implementing and managing complex revenue models. Our first-of-its-kind Agile Monetization platform was purpose-built to enable forward-thinking CFOs, Product, Revenue, and Business owners to quickly and easily adapt their revenue strategy without needing expensive development or consulting resources. Monetize360’s no-code platform has an innovative Intelligence HUB at its core that mediates and rates data from virtually any source, enabling complex relationships and business rules to be created, modified, and deployed in as little as a few hours. The result is greater business agility, faster time-to-market, increased top-line revenue and NRR, and reduced churn.

About TurnCare
Turncare is dedicated to transforming patient care through better Patient Management. Using patented VasoTactic technology that prevents the compression of the sacral region vasculature, TurnCare provides a hardware enabled patient management service that helps hospitals manage their complex high-acuity patients. TurnCare’s mission is to reduce adverse event rates, increase early mobility, and enable care plan flexibility without creating more work for nursing.

Media Contact

Meaghan Shields, Monetiz360, 6175296357, [email protected], www.monetize360.com

SOURCE Monetiz360

Health: Addiction

Top Rated Physical Therapy Group Secures Partnership with University of Louisville Athletics

Leave a comment


“We are delighted to be partnering with Louisville Athletics for the upcoming athletic season,” said PRPT’s CEO, Pat Wempe, PT, DPT, SCS, CSCS. “We look forward to our association with exceptional student athletes who embody the same values that are important to our company – working hard and having fun.”

With over 15 physical therapy practices across Kentucky, PRPT prides itself on delivering the best care and results to its patients through proven research, innovative treatments and technologies. This, along with a longstanding business relationship with Confluent Health, a Louisville-based family of physical and occupational therapy companies spanning the nation, and shared management services associated with it, PRPT is considered one of Kentucky’s top rated physical and occupational therapy experts.

CEO of Confluent Health, Dr. Kristi Henderson, DNP, FAAN, also expressed her enthusiasm for the partnership, stating, “We are excited to see ProRehab Physical Therapy collaborate with University of Louisville Athletics. The partnership aligns perfectly with our mission to positively impact the communities we serve by delivering best-in-class musculoskeletal care and advancing physical therapy practices through evidence-based research.”

In addition, Founder and Executive Chairman of Confluent Health, Dr. Larry Benz, PT, DPT, OCS, MBA, MAPP, FAPTA, has a rich history with the University of Louisville having served in multiple past and current roles with the University of Louisville’s Board of Trustees. Dr. Benz’s deep involvement with the university and its athletic association infuses this partnership with a sense of shared history and potential.

“The partnership between ProRehab Physical Therapy and University of Louisville Athletics has created a power team between top-tier physical therapists and top-performing collegiate athletes,” added Dr. Benz. “I am confident in PRPT’s top-notch care and results through proven research, innovative treatments and technologies, and an approach that treats patients like family. I could not be more thrilled to watch the partnership between PRPT and UofL bloom.”

To learn more about PRPT or to book a free consultation with one of Kentucky’s experts in physical therapy, please visit prorehab.com. 
About ProRehab Physical Therapy: ProRehab Physical Therapy (PRPT) is a Kentucky-based, private physical therapy practice group. As a proud member of the Confluent Health family, PRPT positively impacts patients’ lives by delivering the best care and results through proven research, innovative treatments and technologies, and an approach that treats patients like family. For more information, visit prorehab.com, or find them on Facebook at @prorehablou.

About Confluent Health: Confluent Health is a family of physical and occupational therapy companies. We are transforming healthcare by strengthening private practices, developing highly effective clinicians, innovating new services and technology to improve the quality of care for patients, and lowering costs via more effective treatment, workplace wellness, and injury prevention. For more information, visit goconfluent.com or find us on Facebook at @confluenthealth.

Media Contact

Samantha Grimsley, Confluent Health, 502-472-9674, [email protected], https://goconfluent.com/

SOURCE Confluent Health

Health

Neurotech wellness company Roga partners with major Indian telehealth company

Leave a comment


$35 Million Contract Marks First International Deal & First Healthcare Partnership for the Wearable Pioneer

SAN DIEGO, Aug. 23, 2023 /PRNewswire-PRWeb/ — Neurotech wellness company Roga announced today that it has partnered with GlobalSpace Technologies Ltd. (“GlobalSpace”), India’s first telehealth company, with a $35 million contract. This signals the first major healthcare deal for Roga, as well as its official global expansion beyond the U.S.

Earlier this year, Roga announced it would begin its B2B corporate partnerships program to provide the Roga stress-relief platform to a company’s employees as part of its benefits packages. In addition, Roga also launched its D2C offering in late 2022; consumers in the U.S. can purchase a Roga device directly from the company and download the companion app on iPhones and Androids.

In partnering with GlobalSpace however, Roga is now making its foray into offering white-label services to healthcare companies worldwide to provide the Roga platform to patients directly. While this deal is the first such healthcare partnership for Roga, CEO Ami Lebendiker says this is part of the company’s strategic vision and will be the first of many partnerships. It also marks Roga’s strategic expansion beyond the U.S. market.

“Partnering with healthcare providers and companies has always been part of Roga’s vision, as has been making our devices available to people outside the U.S.,” said Lebendiker. “Stress is a global epidemic. Poor mental health is affecting people’s quality of life around the world. We intend to be able to help people wherever they are, and today’s partnership with one of the leading telehealthcare companies in India is a step in that direction.”

According to a 2017 study, some 44.9 million people in India were reported to be suffering from anxiety related mental health issues, while a 2020 study reported 88% of all Indians suffering from stress and 88% from anxiety. Yet the country was shown to have just 0.75 psychiatrists per 100,000 people. Telehealth has been touted as a critical part of the solution by connecting people to care via their mobile devices – hence a mobile device like Roga can be a benefit.

The Roga device plugs into any phone and runs on the accompanying app, so users can use it anytime they need it. The wearable device sits behind the ears like a pair of headphones and emits a gentle electrical signal that targets the brain’s fight-or-flight response and encourages alpha brain waves, which are associated with calm focus.

Because Roga is mobile, easy-to-use, and low-cost, it is therefore more accessible to the general population, particularly for those who may not have easy access to other forms of mental health support.

“As a telehealth innovator in India, GlobalSpace and Roga were aligned on our core values of providing care in a convenient, accessible, and cutting-edge way that allows us to reach more people wherever they are,” said GlobalSpace Technologies Ltd. CEO Krishna Singh.

GlobalSpace’s DocExa platform is used by over 50,000 healthcare professionals (HCPs) who serve thousands of patients daily dealing with high levels of stress and anxiety. DocExa helps HCPs manage appointments and medical records. It also offers patients a virtual talk therapy program which was designed to help alleviate the issue of access to mental health professionals in India.

Under the agreement, GlobalSpace and Roga will create a new platform called GoRoga, an exclusive for India, that combines the DocExa offerings with Roga’s devices. With GoRoga, HCPs will be able to refer their patients to the Roga device in addition to their existing tools. Because Roga targets the physiological symptoms of stress, this can help complement talk therapy and other methods to create a more well-rounded approach to supporting patients’ mental health. This means patients will be able to access physician care, virtual talk therapy, and the Roga device, all through the GoRoga platform on their phones.

More broadly, GlobalSpace and Roga are partnering to create an ecosystem to promote mental health and wellness in India, assisting patients in managing stress and anxiety, tracking their progress, and engaging in holistic mental wellness practices.

“We’re so proud to be able to partner with GlobalSpace on this effort,” added Lebendiker. “We’re confident this can help meaningfully improve quality of life for a lot of people in India and around the world, and we’re thrilled to see it coming to fruition.”

About Roga:

Roga is a mental health and wellness company using the latest in Neurotech and AI to relieve severe stress and burnout in a convenient, cost-effective way. Based in San Diego and Toronto, Roga was founded in 2020 and launched its inaugural product in 2022. The Roga Life™ is a paired wearable/app duo that combines two proven methods – peripheral nerve stimulation and personalized guided meditations into one safe, effective, and affordable solution. Roga is a VC funded startup and has received multiple research grants.

About GlobalSpace Technologies Ltd.:

GlobalSpace Technologies Ltd. being the thought leaders in pharma digital solutions plays a deep and meaningful role in powering the future of healthcare. We partner with Global and India’s leading life sciences organizations to help them navigate the intricacies of a rapidly converging healthcare industry. With end-to-end offerings across consulting, healthcare solutions, products and digital marketing solutions we empower organizations to optimize their business by leveraging technology and keeping pace with changing environments. Our exclusive focus on the healthcare and life sciences markets enables us to offer domain-centric solutions, services and platforms to our clients that are business focused and outcome based.

Media Contact

Hannah Golden, Roga, 1 (510) 817 – 2218, [email protected], www.rogalife.com

SOURCE Roga

health and fitness

Boston IVF Welcomes Reproductive Endocrinologist Ann Korkidakis, MD to its Waltham & Worcester Fertility Center Teams

Leave a comment


The addition of Dr. Ann Korkidakis to Boston IVF and its Massachusetts fertility centers in Worcester and Waltham bolsters the availability of prompt reproductive care for individuals aspiring to create a family.

WALTHAM, Mass., Aug. 22, 2023 /PRNewswire-PRWeb/ — Boston IVF, one of the world’s most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce that reproductive endocrinologist, Ann Korkidakis, MD has joined its practice and physician team.

Dr. Korkidakis is now accepting new patients at all of Boston IVF’s fertility centers in Massachusetts via telemedicine and in person at the Worcester and Waltham, Massachusetts locations. She specializes in a comprehensive array of infertility treatments and family building services, including, intrauterine insemination (IUI), in vitro fertilization (IVF), egg freezing, LGBTQ+ family building services, recurrent pregnancy loss, PCOS, and more.

Her current research interests include early embryo development, recurrent pregnancy loss, and ongoing barriers to fertility care.

A native of Montreal, Quebec – she is fluent in French and Greek.

Alongside her role as a fertility doctor, Dr. Korkidakis is a member of the American Society for Reproductive Medicine (ASRM), the New England Fertility Society (NEFS), the Pacific Coast Reproductive Society (PCRS), the Canadian Fertility and Andrology Society (CFAS), and the American College of Obstetricians and Gynecologists (ACOG).

“As a former reproductive fellow at Beth Israel Deaconess Medical Center and Boston IVF – we know firsthand the talent and expertise that Dr. Korkidakis brings to our Boston IVF fertility treatment team and are thrilled to have her join us.,” said David Stern, CEO of Boston IVF.

The Beth Israel Deaconess Medical Center/Boston IVF Reproductive Endocrinology and Infertility (REI) Fellowship program is amongst the most prestigious and intensive in the world, equipping fertility doctors with superior training, research, and empathy to help their patients build a family through assisted reproductive technology.

“To join Boston IVF and have the unique opportunity to work alongside such esteemed mentors is truly a great honor,” said Ann Korkidakis, MD. “I look forward to continuing in my role as a trusted resource for my patients in Waltham, Worcester, and across the state of Massachusetts.”

Double-board certified in OB/GYN and REI, Dr. Korkidakis earned her medical degree at McGill University, completed her residency in Obstetrics and Gynecology at Queen’s University, and received her fellowship in Reproductive Endocrinology at both the University of British Columbia in Vancouver and Beth Israel Deaconess Medical Center/Harvard Medical School in conjunction with Boston IVF.

Boston IVF’s Waltham Fertility Center offers a full array of reproductive treatment and care, including on-site andrology and embryology (IVF) laboratories, blood and ultrasound cycle monitoring, male infertility testing, IUI, IVF, egg freezing, and more.

Boston IVF’s Worcester Fertility Center offers a variety of services, including consultations, intrauterine inseminations (IUI), semen analysis, and blood/ultrasound monitoring.

To learn more about Dr. Korkidakis, to receive fertility treatment advice, or to schedule a consultation, visit Boston IVF’s website.

Follow Boston IVF on Instagram

Follow Boston IVF on Linkedin

Follow Boston IVF on Facebook

Follow Boston IVF on Twitter

ABOUT BOSTON IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, Massachusetts, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Media Contact

Zoe Marzi, Boston IVF, 1 781-434-6515, [email protected], https://www.bostonivf.com/

Theo Lopreste, Boston IVF, 1 781-434-6451, [email protected], https://www.bostonivf.com/

Twitter

SOURCE Boston IVF



Health: Psychology

Kvikna Medical Receives European Union MDR Certification

Leave a comment


Regulation MDR (EU) 2017/745 replaces the former European Medical Device Directive (93/42/EEC). The new Regulation describes the requirements and conformity assessment procedures that must be met before medical devices are introduced into the European Economic Area. It was established to set EU-wide rules to improve the safety and quality of medical devices, as well as transparency for patients to protect public health and patient safety. Kvikna Medical’s completion of the new process prior to the extended 2028 deadline helps to ensure the EU market has timely access to new products from the company.

“Stratus EEG is one of the first clinical EEG products to receive MDR certification and we are very proud of this accomplishment”, said Gardar Thorvardson, CEO of Kvikna Medical. “Gaining MDR approval now is a testament to the strength of the company’s quality and risk management systems and the overall caliber of our products. Kvikna Medical is highly committed to excellence in its products and internal processes and always strives to achieve the highest standards. In addition to MDR, the company also has ISO13485 and 14971 certifications.”

To learn more about Stratus EEG software and Kvikna Medical, visit www.stratusEEG.com.

About Kvikna Medical

Kvikna Medical was founded in 2008 to develop and market new and innovative EEG solutions and to make EEG monitoring more accessible to both clinicians and patients. The Stratus EEG™ software is used by thousands of neurologists across the globe to help diagnose and treat people with neurological disorders. Kvikna Medical is a division of Stratus, a privately held company and the largest provider of EEG solutions in the United States.

Media Contact

Jennifer Armstrong, Stratus, 1 9727438992, [email protected], www.stratuseeg.com

SOURCE Stratus

Health: Addiction

Med Schools Fear Board Exam Changes Could Impede Diversity and MD Preparedness

Leave a comment


In January 2022, officials transitioned USMLE Step 1 to a pass/fail model largely to reduce student’s stress and anxiety. However, many educators are not in favor of this change, and residency program directors feel they no longer have a clear, objective way to assess students’ applications for residency. Additionally, the overall USMLE Step 1 pass rates dipped from 88% in 2021 to 82% in 2022. 2

To understand how this change is impacting educators and the students they teach, TrueLearn, a leader in healthcare education whose platform blends data analytics with cognition science to optimize learning outcomes for the medical education community, conducted a survey of more than 250 medical school faculty members, primarily in the U.S. Participants were from institutions such as Duke University School of Medicine, University of California, Los Angeles (UCLA) School of Medicine, Columbia University Vagelos College of Physicians and Surgeons, and University of California San Francisco (UCSF) School of Medicine.

TrueLearn’s survey provides insight into questions like, how is the USMLE Step 1 transition affecting medical students? Is it relieving their stress and anxiety? Will a pass/fail model impede diversity? Will the change result in potentially less prepared and knowledgeable physicians? How are educators dealing with this switch?

Freely available for download, the survey revealed a number of issues and trends including the following:

  • Diversity, equity and inclusion (DEI) was a major concern cited throughout the survey, and 40% of participants believe students – especially those less privileged – will have a tougher time matching into their top choices for residency.
  • Less than half of respondents believe the change will have any positive impact on students’ mental health and well-being.
  • More than half of respondents indicated that 5% or more of their medical students undergo formal remediation or delays each year. When asked if they have the data necessary to identify at-risk students, just 26% of participants stated “yes.”

“Making USMLE pass/fail has been catastrophic to the quality of physicians we are producing and we now only accept applicants from top 10 medical schools. It limits diversity and upward mobility,” wrote one survey participant. “The challenges are immense.”

TrueLearn’s Chief Commercial Officer, Kate Campbell, says, “TrueLearn aims to address these challenges through technology and collaboration. Our goal is to continually innovate technologies and tools that enable educators to understand their students’ strengths and weaknesses and, if necessary, put measures in place to ensure they succeed on their board exams and in their medical career. Vendors, educators, and policymakers must work together to ensure positive outcomes for all medical students and ultimately the patients they treat.”

About TrueLearn

TrueLearn is a leading digital learning and analytics company that focuses on training healthcare professionals in the areas of medicine, nursing, therapy, and allied health. Preparing for high-stakes exams in healthcare is challenging for even the highest performing learners. We help them realize their full potential and support institutions in meeting educational goals. Learn more about TrueLearn here.

1 The Match National Resident Matching Program. Results of the 2021 NRMP Program Director Survey. Nrmp.org. Accessed on August 14, 2023.

2 United States Medical Licensing Examination. Early Release of USMLE Step 1 2022 Summary Performance. USMLE.org. Accessed on August 14, 2023.

Media Contact

Marty Mullarkey, TrueLearn, 650-740-3841, [email protected], www.truelearn.com

Twitter

SOURCE TrueLearn



Health

Finance & Investing Announces Top 25 CFOs in Biotechnology for 2023

Leave a comment


Finance and Investing is pleased to announce The Top 25 CFOs in Biotechnology for 2023

NEW YORK, Aug. 23, 2023 /PRNewswire-PRWeb/ — Finance and Investing is pleased to announce The Top 25 CFOs in Biotechnology for 2023. Biotechnology, tracing back to ancient practices like bread, beer, and wine fermentation, experienced notable growth in the 19th century through advancements like the understanding of microorganisms and Gregor Mendel’s genetic studies. Major figures such as Pasteur and Lister contributed significantly to developments in fermentation and microbial processes. This eventually led to the emergence of prominent medical companies like Gilead Sciences, Amgen, Biogen Idec, and Celgene, contributing to a global biotechnology market estimated at $1.37 trillion in 2022. On top of that, projections show a predicted compound annual growth rate (CAGR) of 13.96% from 2023 to 2030, underscoring the potential for today’s biotech executives to effect meaningful change by bridging scientific innovation and business acumen, thereby catalyzing advancements in healthcare, agriculture, and other critical domains.

An excellent illustration of the advantages that come from combining business and scientific expertise can be seen in Mike Gutch, who holds the position of CFO at Noema Pharma. With both an MBA and a doctorate in cellular and molecular pathology, Gutch has built a substantial career overseeing financial matters for prominent companies in the field of biotechnology. His experience includes financial leadership roles at Entasis Therapeutics and AstraZeneca’s Corporate Development group. Similarly, Marisa Frackman holds the role of CFO at Sapience Therapeutics and boasts a wealth of expertise as a seasoned financial leader, spanning 18 years within the biotechnology capital markets arena. Her career commenced on Wall Street as a member of the Healthcare Investment Banking group at Deutsche Bank Securities. From there, she managed over 250 equity offerings, collectively generating more than $90 billion in funds. Finally, Ryan Jones, who serves as CFO at Kyverna Therapeutics, also contributes an extensive background in the domains of healthcare and life sciences. Notably, Jones holds credit as a co-inventor for five granted patents in the fields of biosensors and DNA sequencing. His involvement extends to serving as a Board Observer for several companies established by GE Ventures, including Menlo Microsystems, Vineti, Drawbridge Health, and Evidation Health.

Please join us in celebrating the accomplishments of The Top 25 CFOs in Biotechnology for 2023.

Alex Garini (Fresenius Kabi USA), Sue Hohenleitner (Johnson & Johnson), Bob Funck (Abbott), John McKenna (Novartis), Patrick Still (Pfizer), Carlos Santos (AstraZeneca), Caroline Litchfield (Merck), Sherry Davis (Eli Lilly and Company), Matt Symonds (Takeda), Zvi Albert (SUN PHARMA US), Andrew Dickinson (Gilead Sciences), Thomas Castellano (Abzena), Marc Belsky (Kezar Life Sciences), Glenn Whaley (Immunic Therapeutics), Ryan Jones (Kyverna Therapeutics), Patricia Dalfo (Hanford Pharmaceuticals), Tony Cords (Quincy Bioscience), Michael Gutch (Noema Pharma), Jon Nunez (Canopy Biosciences), Larry Dalesandro (Genus Lifesciences Inc.), Todd Knapp (Innovive), Noah Clauser (Astria Therapeutics, Inc.), Marisa Frackman (Sapience Therapeutics, Inc.), Rob Middlebrook (Cerevance), and Tiago Girao (Proteovant Therapeutics).

To view the full list, visit https://financeandinvesting.com/the-top-25-cfos-in-biotechnology-for-2023/

About Finance & Investing

Finance & Investing is a comprehensive source for research and information, business news, and corporate actions related to investment banking, wealth management and the public and private markets. The firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on finance and investing and the various firms and executives that make up the sector. Finance & Investing and its affiliates circulate its content to over 38,000 individuals and businesses.

Media Contact

Editor, Finance & Investing, 1 609-365-7014, [email protected], https://financeandinvesting.com/

SOURCE Finance & Investing

health and fitness

First safety outcomes for Rigicon ContiClassic®: Artificial Urinary Sphincter

Leave a comment


The Rigicon ContiClassic® is a new sphincteric device designed to treat male stress urinary incontinence. This study evaluates the surgical outcomes and safety profile of the first 116 patients who received the implant between September 2021 and April 2022.

RONKONKOMA, N.Y., Aug. 23, 2023 /PRNewswire-PRWeb/ — Rigicon, Inc. a leading global innovator of prosthetic urology devices and solutions based in NY proudly announces the recent publication of “First safety outcomes for Rigicon ContiClassic®: Artificial Urinary Sphincter.” The results of the study show the safety outcomes for the Rigicon ContiClassic® to be comparable to others presently on the market which underscores the transformative potential of the Rigicon ContiClassic® in evolving the treatment landscape for male stress urinary incontinence.

Discover more: https://www.nature.com/articles/s41443-023-00748-8

The Rigicon ContiClassic® Artificial Urinary Sphincter is the newest device for treating stress urinary incontinence (SUI) in men and was introduced worldwide two years ago with the first case being implanted in September 2021. The study, meticulously conducted from September 2021 to April 2022, delved into the experiences of the initial 116 patients who underwent the Rigicon ContiClassic® implant procedure. The results arising from this thorough evaluation underline the device’s effectiveness and safety, instilling optimism among those dealing with SUI.

With an in-depth analysis of patient demographics, surgical intricacies, and underlying causes of incontinence, the Rigicon ContiClassic® showcased remarkable efficacy across a diverse patient cohort. Notably, the study’s participants boasted a mean age of 68.3 years, with urinary incontinence post-radical prostatectomy emerging as the predominant reason (58.6%) for implantation. Encouragingly, the study reported no instances of infections or grave complications. A standout highlight of the study was the Kaplan-Meier calculation, unveiling an impressive survival rate of 93.2% at the 12-month juncture.

With a direct quote from the publication, “The ContiClassic® features a hydrophilic coating on all components which allows for antibiotics of the surgeon’s choice to be adsorbed onto the device’s surface for elution into the implant spaces. The connectors of ContiClassic® do not require an assembly tool, and the cuff sizes have smaller increments in diameter (0.25 cm rather than 0.5 cm). An attractive enhancement of the ContiClassic® to the original AMS 800 design involves making the pump of much softer silicone that makes deactivation and activation of the pump much easier for both the physician and the patient. It is hoped this will allow physicians to easily teach their patients nightly deactivation while sleeping.”

Prof. Steven K. Wilson, a renowned authority in urology, lauded the study’s findings, stating, “The Rigicon ContiClassic® signifies a key moment in addressing male stress urinary incontinence. Its combination of innovative design and promising safety outcomes makes it a surefire choice for patients seeking effective solutions.”

Rigicon’s pursuit of excellence in medical device innovation is underlined by the Rigicon ContiClassic®, ready to reshape the narrative surrounding in male stress urinary incontinence treatment.

Rigicon is a global leader in prosthetic urology with products currently available in over 50 countries. A full list of products can be found on the company’s website at www.rigicon.com. Rigicon stands at the forefront of medical innovation, driven by a commitment to enhancing patient care and quality of life. Rigicon ContiClassic® reinforces the company’s dedication to groundbreaking solutions that redefine medical possibilities.

About Rigicon

Rigicon, based in Ronkonkoma, NY, is a pioneering company specializing in the design, development, and manufacturing of innovative urology devices. Our mission is to enhance the quality of patient care with our world-class products, which are developed in close collaboration with top surgeons worldwide. We remain committed to our mission to provide solutions that improve the quality of life for patients around the globe.

Media Contact

Jessica Miranda, Rigicon, Inc., 1 88820290, [email protected], www.rigicon.com

Twitter, LinkedIn

SOURCE Rigicon, Inc.